多囊卵巢综合征排卵障碍的发生机制

摘要/Abstract

摘要： 多囊卵巢综合征(polycystic ovarian syndrome)是一种常见的、复杂的生殖内分泌性及代谢性疾病，通常在青春期和成年期出现，主要以排卵障碍、卵巢呈多囊样改变和高雄激素血症为特征，临床上发病率可达5%～10%，并有逐年升高趋势。多囊卵巢综合征不仅是一种生殖病理，而且是一种全身性的疾病，与明显的内分泌、代谢、心血管、生殖和精神疾病相关，但其发病机制目前尚未明确，国际上多囊卵巢综合征诊断标准也是各国不一。在我国多囊卵巢综合征排卵异常相关的不孕占无排卵性不孕的75%左右，是育龄期女性排卵障碍性不孕症最常见的原因之一，对患者的影响越来越突出。近年来，多囊卵巢综合征排卵障碍的机制研究广受临床关注，为了深入了解多囊卵巢综合征的发病机制及防治，本研究主要围绕多囊卵巢综合征排卵障碍的机制进行综述，深入探讨多囊卵巢综合征的发病机制及防治，以期为临床干预和有效治疗多囊卵巢综合征提供借鉴和参考。

关键词: font-size:medium, ">多囊卵巢综合征；排卵障碍；雄激素；胰岛素抵抗

Abstract: Polycystic ovarian syndrome (PCOS) is a common and complex reproductive endocrine disorder and metabolic disease and usually occures in adolescence and adulthood，which is mainly characterized by ovulation disorder， polycystic ovarian changes and hyperandrogenemia. Its incidence rate is 5%-10% clinically， and it is increasing year by year. PCOS is not only a reproductive pathology， but also a systemic disease， which is related to obvious endocrine， metabolic， cardiovascular， reproductive and mental diseases.However， its pathogenesis is currently unclear. The international diagnostic criteria for PCOS are also different from country to country. Infertility associated with abnormal ovulation in PCOS accounts for about 75% of anovulatory infertility in China. PCOS is one of the most common causes of ovulatory dysfunction infertility in women of childbearing age， and its impact on patients is more and more significant. Therefore， the research on the mechanism of ovulation disorder in PCOS has received extensive attention in recent years. In order to deeply understand the pathogenesis and prevention of PCOS， this paper reviews the research progress on the mechanism of ovulation disorder in PCOS， discusses the pathogenesis and prevention of PCOS in-depth，and provides new ideas for finding effective measures to treat PCOS.

Key words: font-size:medium, ">Polycystic ovarian syndrome； Ovulation dysfunction； Androgen； Insulin resistance

中图分类号:

李晓敏, 黄文洁, 卢永超. 多囊卵巢综合征排卵障碍的发生机制[J]. 中国医药导刊, 2021, 23(7): 486-490.

LI Xiaomin, HUANG Wenjie, LU Yongchao. The Mechanism of Ovulatory Dysfunction in Polycystic Ovarian Syndrome[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(7): 486-490.

参考文献

[1]Ricardo Azziz， Enrico Carmina， ZiJiang Chen， et al. Polycystic ovary syndrome[J]. Nat Rev Dis Primers， 2016， 375(1)：54-64.
     [2]Roy Homburg. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome[J]. Best Pract Res Clin Obstet Gynaecol， 2004， 18(5)：773-788.
     [3]Ricardo Azziz， Eli Y Adashi. Stein and Leventhal： 80 years on[J]. Am J Obstet Gynecol， 2016， 214(2)：241-247.
     [4]Joyce King. Polycystic ovary syndrome[J]. J Midwifery Womens Health， 2006， 51(6)：415-422.
     [5]Erin K Barthelmess， Rajesh K Naz. Polycystic ovary syndrome： current status and future perspective[J]. Front Biosci (Elite Ed)， 2014， 6： 104-119.
     [6]Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J]. Hum Reprod， 2004， 19(1)：41-47.
     [7]Adriana Catharina Helena Neven， Joop Laven， Helena J Teede， et al. A summary on polycystic ovary syndrome：diagnostic criteria， prevalence， clinical manifestationsm， and management according to the latest international guidelines[J]. Semin Reprod Med， 2018， 36(1)：5-12.
     [8]Mohamed Rezk， Haitham Hamza， El-Sayed El-Shamy. Luteal support with vaginal dydrogesterone increases pregnancy rate in patients with clomifene resistant polycystic ovary syndrome receiving letrozole for ovulation induction[J]. Gynecological Endocrinology， 2019， 35(3)：217-219．
     [9]Vivek Pandey， Anusha Singh， Ajit Singh， et al. Role of oxidative stress and low-grade inflammation in letrozole-induced polycystic ovary syndrome in the rat[J]. Reprod Biol， 2016， 16(1)：70-77.
     [10]Bart C J M Fauser， asil C Tarlatzis， Robert W Rebar， et al. Consensus on women′s health aspects of polycystic ovary syndrome (PCOS)：the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J]. Fertil Steril， 2012， 97(1)：28-38.
     [11]Stephen Franks， Jaroslav Stark， Kate Hardy. Follicle dynamics and anovulation in polycystic ovary syndrome[J]. Hum Reprod Update， 2008， 14(4)：367-378.
     [12]Stefano Palomba， Angela Falbo， Giuseppe Chiossi， et al. Lipid profile in nonobese pregnant women with polycystic ovary syndrome： a prospective controlled clinical study[J]. Steroids， 2014， 88： 36-43.
     [13]Dewailly D. Polycystic ovary syndrome [J]. J Gynecol Obstet Biol Reprod (Paris)， 2000， 29(3)：298-301.
     [14]Valentina Rodriguez Paris， Michael J Bertoldo. The Mechanism of Androgen Actions in PCOS Etiology[J]. Med Sci (Basel)， 2019， 7(9)：89.
     [15]Ruth Freeman， Rena Pollack， Ella Rosenbloom. Assessing impaired glucose tolerance and insulin resistance in polycystic ovarian syndrome with a muffin test： an alternative to the glucose tolerance test[J]. Endocr Pract， 2010， 16(5)：810-817.
     [16]Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril， 2004， 81(1)：19-25.
     [17]Pinola P， Morin-Papunen LC， Bloigu A， et al. Anti-Müllerian hormone： correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study[J]. Hum Reprod， 2014， 29（10）： 2317-2325.
     [18]Didier Dewailly， Geoffroy Robin， Maeliss Peigne， et al. Interactions between androgens， FSH， anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary[J]. Hum Reprod Update， 2016， 22（6）： 709-724.
     [19]Cappelli V， Musacchio MC， Bulfoni A， et al. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS[J]. Eur Rev Med Pharmacol Sci， 2017， 21(2 Suppl)：15-29.
     [20]Kathleen M Hoeger， Sharon E Oberfield. Do women with PCOS have a unique predisposition to obesity? [J]. Fertil Steril， 2012， 97(1)：13-17.
     [21]Corbould A. Effects of androgens on insulin action in women： is androgen excess a component of female metabolic syndrome? [J]. Diabetes Metab Res Rev， 2008， 24(7)：520-532.
     [22]Yue Zhao， Li Fu， Rong Li， et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome： plasma metabolomics analysis [J]. BMC Med， 2012， 10： 153.
     [23]Pritam Kumar Panda， Riya Rane， Rahul Ravichandran， et al. Genetics of PCOS： A systematic bioinformatics approach to unveil the proteins responsible for PCOS [J]. Genom Data， 2016， 8： 52-60.
     [24]Ashvini Desai， Inamul Hasan Madar， Amjad Hussain Asangani， et al. Influence of PCOS in Obese vs. Non-Obese women from Mesenchymal Progenitors Stem Cells and Other Endometrial Cells： An in silico biomarker discovery [J]. Bioinformation， 2017， 13(4)：111-115.
     [25]Harrison CL， Teede HJ， Joham AE， et al. Breastfeeding and obesity in PCOS [J]. Expert Rev Endocrinol Metab， 2016， 11(6)：449-454.
     [26]Zahra Shaaban， Arezoo Khoradmehr， Amir Amiri-Yekta， et al. Pathophysiologic mechanisms of obesity- and chronic inflammation-related genes in etiology of polycystic ovary syndrome [J]. Iran J Basic Med Sci， 2019， 22(12)：1378-1386.
     [27]Thomas Reinehr， Alexandra Kulle， Juliane Rothermel， et al. Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss[J]. Endocr Connect， 2017， 6(4)：213-224.
     [28]Neil F Goodman， Rhoda H Cobin， Walter Futterweit， et al. American association of clinical endocrinol ogists， American college of endocrinology， and androgen excess and PCOS society disease state clinical review：Guide to the best practices in the evaluation and treatment of Polycystic Ovary Syndrome - Part 2[J]. Endocr Pract， 2015， 21(12)：1415-1426.
     [29]Yongyong Shi， Han Zhao， Yuhua Shi， et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome[J]. Nat Genet， 2012， 44(9)：1020-1025.
     [30]Shaini Joseph， Ram Shankar Barai， Rasika Bhujbalrao， et al. PCOSKB： A KnowledgeBase on genes， diseases， ontology terms and biochemical pathways associated with polycystic ovary syndrome[J]. Nucleic Acids Res， 2016， 44(D1)：D1032-1035.
     [31]Xita N， Georgiou I， Tsatsoulis A. The genetic basis of polycystic ovary syndrome[J]. Eur J Endocrinol， 2002， 147(6)：717-725.
     [32]Raiane P Crespo， Tania A S S Bachega， Berenice B Mendonca， et al. An update of genetic basis of PCOS pathogenesis[J]. Arch Endocrinol Metab， 2018， 62(3)：352-361.
     [33]Iris Eisenberg， Neta Nahmias， Michal Novoselsky Persky， et al. Elevated circulating micro-ribonucleic acid (miRNA)-200b and miRNA-429 levels in anovulatory women[J]. Fertil Steril， 2017， 107(1)：269-275.
     [34]Muhammad Jaseem Khan， Anwar Ullah， Sulman Basit. Genetic Basis of Polycystic Ovary Syndrome (PCOS)：Current Perspectives[J]. Appl Clin Genet， 2019， 12： 249-260.
     [35]Jana Petríková， Ivica Lazúrová， Shoenfeld Yehuda. Polycystic ovary syndrome and autoimmunity[J]. Eur J Intern Med， 2010， 21(5)：369-371.
     [36]Qun Yu， Jin-Bei Wang. Subclinical hypothyroidism in PCOS： impact on presentation， insulin resistance， and cardiovascular risk[J]. Biomed Res Int， 2016， 2016： 2067087.
     [37]Seema Patel. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments： A comprehensive review[J]. J Steroid Biochem Mol Biol， 2017， 168： 19-25.
     [38]Hifsa Mobeen， Nadeem Afzal， Muhammad Kashif. Polycystic ovary syndrome may be an autoimmune disorder[J]. Scientifica (Cairo)， 2016， 2016： 4071735.

快速检索引用检索图表检索高级检索